Product Description
Furosemide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine. urosemide is used alone or in combination with other medications to treat high blood pressure. Furosemide is used to treat edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including heart, kidney, and liver disease. (Sourced from: https://medlineplus.gov/druginfo/meds/a682858.html)
Mechanisms of Action: NKCC Inhibitor,TGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: scPharmaceuticals
Company Location: BURLINGTON MA 01803
Company CEO: John H. Tucker
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Czech Republic, Denmark, Germany, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pain Unspecified
Phase 2: Adenocarcinoma|Dyspnea|Heart Failure|Prostate Cancer
Phase 1: Healthy Volunteers|Malaria
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2024-510792-38-01 | P3 |
Withdrawn |
Pain Unspecified |
2029-03-01 |
2025-05-02 |
Treatments |
|
| STUDY00004720 | P2 |
Active, not recruiting |
Prostate Cancer|Adenocarcinoma |
2027-07-01 |
32% |
2024-03-28 |
Primary Endpoints|Treatments|Trial Status |
| INFURO_2023 | P2 |
Recruiting |
Dyspnea |
2026-01-01 |
2025-05-02 |
Treatments |
|
| scP-04-001 | P1 |
Completed |
Heart Failure |
2024-06-14 |
12% |
2024-06-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| ACTRN12621001218886 | P1 |
Completed |
Malaria |
2023-01-18 |
2024-08-29 |
Treatments |
|
| 2024-510792-38-00 | P3 |
Withdrawn |
Pain Unspecified |
2029-03-01 |
2025-05-02 |
Treatments |
|
| D9440C00002 | P1 |
Recruiting |
Healthy Volunteers |
2025-06-11 |
69% |
2025-05-15 |
|
| U1111-1302-1171 | P1 |
Completed |
Healthy Volunteers |
2024-10-03 |
69% |
2024-12-21 |
Primary Endpoints|Treatments|Trial Status |
| RESISTANCE-HF | P2 |
Completed |
Heart Failure |
2024-04-22 |
50% |
2024-12-19 |
Primary Endpoints|Study Completion Date |
| CTR20230743 | P1 |
Completed |
Healthy Volunteers |
2024-02-02 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| D5084C00014 | P1 |
Completed |
Healthy Volunteers |
2023-06-24 |
23% |
2023-07-14 |